С. В. Орлов

14.2k total citations · 4 hit papers
106 papers, 6.6k citations indexed

About

С. В. Орлов is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, С. В. Орлов has authored 106 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 45 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in С. В. Орлов's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (14 papers). С. В. Орлов is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (14 papers). С. В. Орлов collaborates with scholars based in Russia, United States and Germany. С. В. Орлов's co-authors include Lecia V. Sequist, Vera Hirsh, James Chih‐Hsin Yang, В. А. Горбунова, Sarayut Lucien Geater, Tony Mok, Wu‐Chou Su, Jaafar Bennouna, Michael Boyer and Mehdi Shahidi and has published in prestigious journals such as JAMA, The Journal of Chemical Physics and Journal of Clinical Oncology.

In The Last Decade

С. В. Орлов

85 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

2014 694 citations Martin Reck, С. В. Орлов et al. profile →
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2013 370 citations David R. Spigel, Fabrice Barlési et al. Journal of Clinical Oncology profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
С. В. Орлов Russia	27	4.6k	4.0k	2.1k	1.0k	513	106	6.6k
Ferry A.L.M. Eskens Netherlands	43	1.5k 0.3×	2.9k 0.7×	2.6k 1.2×	1.2k 1.2×	694 1.4×	161	6.4k
Thomas E. Stinchcombe United States	41	3.7k 0.8×	3.9k 1.0×	1.7k 0.8×	824 0.8×	141 0.3×	215	6.9k
Helen X. Chen United States	37	2.6k 0.6×	4.1k 1.0×	3.9k 1.8×	2.0k 1.9×	476 0.9×	84	8.9k
Tae‐You Kim South Korea	37	2.4k 0.5×	3.3k 0.8×	3.1k 1.5×	1.8k 1.7×	324 0.6×	150	7.6k
Vassilis Georgoulias Greece	46	2.8k 0.6×	5.7k 1.4×	1.9k 0.9×	2.8k 2.7×	428 0.8×	182	7.3k
Daniel Morgensztern United States	36	4.5k 1.0×	5.4k 1.3×	3.9k 1.8×	2.2k 2.1×	221 0.4×	228	10.4k
Anatoly Makhson Russia	7	1.9k 0.4×	4.2k 1.0×	810 0.4×	698 0.7×	1.2k 2.3×	11	5.3k
K. Mross Germany	37	1.0k 0.2×	3.1k 0.8×	2.1k 1.0×	606 0.6×	395 0.8×	148	5.2k
Scott Gettinger United States	58	6.8k 1.5×	10.3k 2.6×	2.8k 1.3×	1.7k 1.7×	219 0.4×	258	13.2k
Craig Devoe United States	17	3.9k 0.9×	10.3k 2.6×	2.3k 1.1×	1.3k 1.2×	193 0.4×	47	12.7k

Countries citing papers authored by С. В. Орлов

Since Specialization

Citations

This map shows the geographic impact of С. В. Орлов's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by С. В. Орлов with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites С. В. Орлов more than expected).

Fields of papers citing papers by С. В. Орлов

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by С. В. Орлов. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by С. В. Орлов. The network helps show where С. В. Орлов may publish in the future.

Co-authorship network of co-authors of С. В. Орлов

This figure shows the co-authorship network connecting the top 25 collaborators of С. В. Орлов. A scholar is included among the top collaborators of С. В. Орлов based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with С. В. Орлов. С. В. Орлов is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reva, Viktor, et al.. (2025). Emergency Ultra-Deep Hypothermia in Cardiac Arrest Induced by Blood Loss (Experimental Study on Nonhuman Primates). General Reanimatology. 21(1). 62–74. 1 indexed citations

Lazareva, Anna, et al.. (2025). Cardiac Lymph Flow Features and New Opportunities for Their Experimental Visualization. Doklady Biochemistry and Biophysics. 520(1). 20–24. 1 indexed citations

Орлов, С. В., et al.. (2024). Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports. Voprosy Onkologii. 70(2). 384–389.

Imyanitov, Evgeny N., Elena V. Preobrazhenskaya, & С. В. Орлов. (2024). Current status of molecular diagnostics for lung cancer. SHILAP Revista de lepidopterología. 5(3). 742–765. 3 indexed citations

Sokolenko, Anna P., et al.. (2024). <I>BRCA1/2</I> mutation spectrum in Armenian patients with breast and ovarian cancers. SHILAP Revista de lepidopterología. 22(6). 83–91. 1 indexed citations

Назаров, В. Д., et al.. (2023). Molecular genetics features of anaplastic thyroid carcinoma. Russian Journal of Oncology. 27(2). 59–70.

Garon, Edward B., Shun Lü, Yasushi Goto, et al.. (2023). Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. Journal of Clinical Oncology. 42(2). 180–191. 41 indexed citations

Hartmaier, Ryan J., Aleksandra Markovets, Myung‐Ju Ahn, et al.. (2022). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. 13(1). 98–113. 95 indexed citations breakdown →

Бредер, В. В., Evgeny N. Imyanitov, К. К. Лактионов, et al.. (2022). Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by <i>NTRK</i> gene fusions“. SHILAP Revista de lepidopterología. 50–56.

10.

Назаров, В. Д., et al.. (2022). Molecular markers of endometrial carcinoma and associated clinicopathological features. 20(3). 34–40.

11.

Morgensztern, Daniel, Nina Karaseva, Enriqueta Felip, et al.. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 136. 74–79. 19 indexed citations

12.

Scagliotti, Giorgio V., Dale E. Shuster, С. В. Орлов, et al.. (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. Journal of Thoracic Oncology. 13(6). 849–854. 37 indexed citations

13.

Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations

14.

Орлов, С. В., et al.. (2016). IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?. SHILAP Revista de lepidopterología. 3(2). 45–52. 1 indexed citations

15.

Орлов, С. В., et al.. (2016). SUCCESSFUL REGISTRATION OF DOMESTIC BIOANALOGUE OF BEVACIZUMAB – NEW OPPORTUNITIES FOR EFFECTIVE TREA TMENT OF PATIENTS WITH NON-SQUAMOUS CELL NON-SMALL CELL LUNG CANCER. SHILAP Revista de lepidopterología. 2(4). 132–136. 4 indexed citations

16.

Горбунова, В. А., et al.. (2015). Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene. Malignant tumours. 35–35. 1 indexed citations

17.

Орлов, С. В., et al.. (2014). The experience of dynamic fixation with nitinol implants for degenerative diseases of the spine. Genij Ortopedii. 1 indexed citations

18.

Mok, Tony, В. А. Горбунова, Erzsébet Juhász, et al.. (2014). A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015). Journal of Thoracic Oncology. 9(6). 848–855. 39 indexed citations

19.

Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334. 2461 indexed citations breakdown →

20.

Ready, Neal, Nina Karaseva, С. В. Орлов, et al.. (2011). Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(4). 781–785. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact